Lanreotide
FDA-approved depot somatostatin analog (Somatuline Depot).
What it's for
FDA-approved depot somatostatin analog (Somatuline Depot).
What it's for
Lanreotide is a synthetic somatostatin 8–amino-acid peptide analog formulated as a deep under-the-skin depot. It treats acromegaly and certain unresectable, well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors, and can improve symptoms of carcinoid syndrome per labeling.
What it does for the body
It treats acromegaly and certain unresectable, well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors, and can improve symptoms of carcinoid syndrome per labeling.
What it targets
It binds somatostatin receptors (lock-and-key landing spots on cells), suppressing excess growth hormone/IGF-1 and inhibiting secretory activity of some neuroendocrine tumor cells. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Lanreotide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Lanreotide — FDA.gov search
- ClinicalTrials.gov search: Lanreotide — U.S. clinical trials registry
- Drugs@FDA search: Lanreotide — FDA drug database (if approved)
- PubMed search: Lanreotide — NCBI PubMed
- PubMed Central search: Lanreotide — NCBI PMC